Bioxcel Therapeutics Logo
Previous slide
Next slide

Our AI-based approach is designed to:

  • Enhance R&D efficiencies
  • Shorten development timelines
  • Increase probability of success

Latest News

VIEW ALL NEWS
Nov 22, 2024
BioXcel Therapeutics Announces Pricing of $7.0 Million Public OfferingVIEW RELEASE
Nov 21, 2024
BioXcel Therapeutics Announces Proposed Public OfferingVIEW RELEASE
Nov 14, 2024
BioXcel Therapeutics Reports Third Quarter 2024 Financial ResultsVIEW RELEASE
VIEW ALL NEWS

Stock Information

BioXcel Therapeutics, Inc.

Dec 03, 2024 11:51 AM

MARKET/SYMBOL

Nasdaq:

BTAI

PRICE

0.4201

CHANGE

-0.01 (-2.33%)
EVENTS
SIGN UP FOR EMAIL ALERTS
Bioxcel Therapeutics Logo
Linkedin-in Twitter

IGALMI is a trademark of BioXcel Therapeutics, Inc. 
All other trademarks are the properties of their respective owners.
Copyright © 2024 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

All other trademarks are the properties of their respective owners.
Copyright © 2023 BioXcel Therapeutics Inc. All Rights Reserved. US-IGA-2300177

Scroll to Top

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries. This web site is intended to help healthcare professionals practicing in the US find scientifically balanced, evidence-based information about Bioxcel Therapeutics drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.